Therefore, this review aims to comprehensively examine the involvement of the IGF axis in MDS and AML, highlight its crosstalk with other oncogenic pathways, and summarize the current progress and challenges in targeting IGF signaling as a therapeutic strategy. The gene discussed is IGF1; the disease is myelodysplastic syndrome.